UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 52,423 Shares of Solventum Co. (NYSE:SOLV)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Solventum Co. (NYSE:SOLV) by 5.0% in the 4th quarter, Holdings Channel reports. The fund owned 1,106,194 shares of the company’s stock after purchasing an additional 52,423 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Solventum were worth $73,075,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Clarity Asset Management Inc. bought a new stake in shares of Solventum in the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC bought a new position in Solventum in the fourth quarter worth $26,000. Raiffeisen Bank International AG bought a new position in Solventum in the fourth quarter worth $29,000. Crews Bank & Trust bought a new position in Solventum in the fourth quarter worth $32,000. Finally, Colonial Trust Co SC lifted its position in Solventum by 240.7% in the fourth quarter. Colonial Trust Co SC now owns 511 shares of the company’s stock worth $34,000 after purchasing an additional 361 shares during the period.

Wall Street Analyst Weigh In

Several brokerages recently commented on SOLV. Mizuho raised their target price on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Piper Sandler raised Solventum from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $78.00 to $87.00 in a research report on Monday, May 19th. Wells Fargo & Company raised their target price on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Morgan Stanley raised their target price on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. Finally, Bank of America raised their target price on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $80.29.

Solventum Stock Performance

Solventum stock opened at $70.85 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a fifty day moving average price of $69.71 and a two-hundred day moving average price of $71.29. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The firm has a market capitalization of $12.26 billion and a P/E ratio of 32.80.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.15. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. During the same quarter in the prior year, the company earned $2.08 earnings per share. The business’s revenue was up 2.7% compared to the same quarter last year. As a group, analysts anticipate that Solventum Co. will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.